Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LLYBullishIndustry Newsnews

High materiality7/10

Lilly's Taltz and Zepbound show durable 52-week efficacy in PsO/PsA with obesity

Aug 31, 2026, 7:19 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 3b data showing durable efficacy in obesity-linked psoriatic diseases could lift near-term sentiment, with longer-term upside contingent on regulatory clearance and payer uptake.

AI summary

What happened, with direct paths to the underlying reporting

Lilly disclosed 52-week results from TOGETHER-PsO and TOGETHER-PsA, showing that Taltz and Zepbound together preserved or deepened improvements in skin and joint disease while improving systemic inflammation and metabolic markers in obese patients. The data are exploratory and open-label, but they underscore a potential immunometabolic treatment approach that could broaden Lilly's addressable market if validated in later trials and regulatory approval.

52-week data show Taltz+Zepbound sustain improvements vs Taltz alone.
Primary outcomes: PASI100+≥10% weight loss in PsO reached 30.6% vs 4.4%.
PsA: ACR50+≥10% weight loss at Week 52 reached 39.2% vs 1.7%.
Adverse events were mild/moderate; safety profile consistent with known data.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Lilly's Taltz and Zepbound show durable 52-week efficacy in PsO/PsA with obesity

FDA approves Lilly drug combo for metastatic breast cancer, boosting near-term upside

LLY Gains on Positive EASD Pipeline Previews and Strong Q2 Beat

Lilly narrows obesity oral-treatment gap vs Novo Nordisk, signaling momentum

Low-Dose GLP-1 Obesity Drug Study Signals Dosing Shift for Lilly